Eli Lilly and Company (NYSE:LLY) Shares Purchased by Deutsche Bank AG

Key Points

• Deutsche Bank AG increased its stake in Eli Lilly by 15.8%, owning over 3.5 million shares which account for 1.1% of its portfolio, making it the bank's 9th largest holding.
• Eli Lilly reported a strong quarterly earnings of $6.31 per share, surpassing estimates, with revenue of $15.56 billion, marking a 37.6% year-over-year increase.
• The company announced a quarterly dividend of $1.50, with a yield of 0.9%, scheduled for payment on September 10th, and a dividend payout ratio of 48.82%.

Deutsche Bank AG grew its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 15.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,503,528 shares of the company's stock after purchasing an additional 477,889 shares during the period. Eli Lilly and Company makes up 1.1% of Deutsche Bank AG's holdings, making the stock its 9th largest position. Deutsche Bank AG owned approximately 0.37% of Eli Lilly and Company worth $2,893,599,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of LLY. WestEnd Advisors LLC raised its position in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after buying an additional 21 shares during the last quarter. Citizens National Bank Trust Department increased its stake in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after acquiring an additional 27 shares during the period. Financial Gravity Asset Management Inc. purchased a new position in shares of Eli Lilly and Company during the 1st quarter valued at about $40,000. Mascagni Wealth Management Inc. acquired a new position in Eli Lilly and Company in the fourth quarter valued at approximately $43,000. Finally, O Brien Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 25.5% during the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after purchasing an additional 12 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Eli Lilly and Company

In other news, Director Jamere Jackson acquired 200 shares of the firm's stock in a transaction dated Friday, August 8th. The stock was acquired at an average cost of $639.56 per share, with a total value of $127,912.00. Following the transaction, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.13% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

LLY has been the topic of several recent analyst reports. Leerink Partnrs lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday. Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Wall Street Zen raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Morgan Stanley reaffirmed an "overweight" rating and set a $1,135.00 price objective (up previously from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Finally, UBS Group decreased their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research note on Friday. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and an average price target of $990.89.

Eli Lilly and Company Trading Down 2.5%

LLY stock traded down $15.71 during mid-day trading on Friday, hitting $625.15. 14,089,857 shares of the company were exchanged, compared to its average volume of 4,833,475. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $972.53. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. The business has a fifty day simple moving average of $776.36 and a 200-day simple moving average of $799.60. The firm has a market capitalization of $592.48 billion, a P/E ratio of 40.86, a PEG ratio of 0.91 and a beta of 0.44.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 98.25% and a net margin of 25.91%. Eli Lilly and Company's revenue was up 37.6% compared to the same quarter last year. During the same period in the previous year, the company posted $3.92 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 1.0%. Eli Lilly and Company's payout ratio is currently 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.